David M Rayner 25th Lorne Cancer Conference 2013

Abstracts this author is presenting:

• Shifting doxorubicin activity from topoisomerase2 poison to adduct formation reduces cardiotoxicity while maintaining anticancer efficacy — Poster Session 2